Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 13, 2015, Pages 2342-2349.e2

  Keskin, Onur ^a   Wedemeyer, Heiner ^b   Tüzün, Ali ^a   Zachou, Kalliopi ^c   Deda, Xheni ^a   Dalekos, George N ^c   Heidrich, Benjamin ^b   Pehlivan, Selcen ^d   Zeuzem, Stefan ^e   Yalçin, Kendal ^f   Gürel, Selim ^g   Tabak, Fehmi ^h   Idilman, Ramazan ^a   Bozkaya, Hakan ^a   Manns, Michael ^b   Yurdaydin, Cihan ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF THESSALY   (Greece)

^d Yildirim Beyazit University Medical School   (Turkey)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f DICLE UNIVERSITY   (Turkey)

^g ULUDAG UNIVERSITY   (Turkey)

^h ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Chronic Delta Hepatitis; On Treatment HDV RNA; Pegylated Interferon Treatment; Treatment Outcome Prediction

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; HEPATITIS B SURFACE ANTIGEN; LIVER ENZYME; PEGINTERFERON ALPHA2A; PLACEBO; VIRUS DNA; VIRUS RNA; ADENINE; ALPHA INTERFERON; AMINOTRANSFERASE; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MALE; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BIOPSY; BLOOD; CLINICAL TRIAL; GENETICS; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VIRUS LOAD;

ADENINE; ADULT; ANTIVIRAL AGENTS; BIOPSY; DNA, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PLACEBOS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RNA, VIRAL; TRANSAMINASES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84947244327     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.05.029     Document Type: Article

References (24)

1. Yurdaydin C. Treatment of chronic delta hepatitis. Sem Liver Dis 2012, 32:237-244.
2. Günşar F., Akarca U.S., Ersöz G., et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 2005, 10:721-726.
3. Di Marco V., Giacchino R., Timitilli A., et al. long-term interferon-α treatment of children with chronic hepatitis delta: a multicentre study. J Viral Hepat 1996, 3:123-128.
4. Yurdaydin C., Bozkaya H., Karaaslan H., et al. A pilot study of two years of interferon in patient with chronic delta hepatitis. J Viral Hepat 2007, 14:812-816.
5. Yurdaydin C., Bozkaya H., Önder F.O., et al. Treatment of chronic delta hepatitis with lamivudine vs. lamivudine + interferon vs. interferon. J Viral Hepat 2008, 15:314-321.
6. Castelnau C., Le Gal F., Ripault M.P., et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006, 44:728-735.
7. Kabaçam G., Yakut M., Seven G., et al. Delta hepatitis may require prolonged treatment with interferon (abstr). Hepatology 2011, 54:1039A.
8. Lau D.T., Kleiner D.E., Park Y., et al. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 1999, 117:1229-1233.
9. Kabaçam G., Dalekos G.N., Çakaloğlu Y., et al. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turk J Gastroenterol 2012, 23:560-568.
10. Rijckborst V., Hansen B.E., Cakaloglu Y., et al. Early on-treatment prediction of response to peginterferon alfa 2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010, 52:454-461.
11. Brunetto M.R., Moriconi F., Bonino F., et al. Hepatitis B surface antigen levels: a guide to sustained response to pegylated interferon alfa 2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49:1141-1150.
12. Wedemeyer H., Yurdaydin C., Dalekos G.N., et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011, 364:322-331.
13. Zachou K., Yurdaydin C., Drebber U., et al. Quantitative HBsAg and HDV RNA levels in chronic delta hepatitis. Liver Int 2010, 30:430-437.
14. Ruopp M.D., Perkins N.J., Whitcomb B.W., et al. Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J 2008, 50:419-430.
15. Wöbse M., Yurdaydin C., Ernst S., et al. Early on-treatment HDV RNA kinetics are not predictive for long-term response to a PEG-IFNa therapy of hepatitis delta (abstr). Hepatology 2014, 60:974A.
16. Guedj J., Rotman Y., Cotler S.J., et al. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematic modeling. Hepatology 2014, 60:1902-1910.
17. Brunetto M.R., Marcellin P., Cherubini B., et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 2013, 59:1153-1159.
18. Karaca Ç., Soyer O.M., Baran B., et al. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther 2013, 18:561-566.
19. Niro G.A., Ciancio A., Gatea G.B., et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006, 44:713-720.
20. Yilmaz E., Baran B., Soyer O.M., et al. Effects of polymorphisms in interferon λ3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection. Clin Gastroenterol Hepatol 2014, 12:1753-1758.
21. Visco-Comandini U., Lapa D., Taibi C., et al. No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance. Dig Liver Dis 2014, 46:348-352.
22. Heidrich B., Yurdaydin C., Kabaçam G., et al. Late HDV RNA relapse after peginterferon alfa-based therapy of chronic hepatitis delta. Hepatology 2014, 60:87-97.
23. Wedemeyer H., Yurdaydin C., Ernst S., et al. 96 weeks of pegylated interferon alfa-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 Study (abstr). Hepatology 2013, 58:222A.
24. Chudy M., Hanschmann K.-M., Bozdayi A.M., et al. Collaborative study to establish a World Health Organization international standard for hepatitis D virus RNA for nucleic acid amplification technique (NAT)-based assays. Expert Committee Meeting on biological standardization. WHO/BS/2013.2227. Geneva October 21-25, 2013.